Department of Surgical Pathology, Aichi Medical University Hospital, Aichi, Japan.
Department of Urology, Minato Medical Coop-Kyoritsu General Hospital, Tokyo, Japan.
Pathol Int. 2020 Oct;70(10):743-751. doi: 10.1111/pin.12997. Epub 2020 Aug 9.
Management of advanced hormone-naïve prostate cancer (HNPC) is a critical public health issue. Useful prognostic markers are thus needed to select patients who will benefit from recently introduced upfront therapies. p16 expression is an adverse prognostic marker in prostate cancer. The present study aimed to determine whether p16 expression would serve as an adverse prognostic marker in advanced HNPC. A total of 79 patients diagnosed by needle biopsy with adenocarcinoma Gleason score ≥8 between 2010 and 2013 at Aichi Medical University were included in this study. The median patient age was 73 (range 52-87) years. The median follow-up was 62 months (range 2-98). Fourteen patients had p16-positive samples. Fifteen patients died from prostate cancer, 10 of whom were in the p16-positive group. p16 positivity was associated with clinical T stage (P < 0.001), presence of IDC-P (P < 0.001), distant metastasis (P < 0.001) and lymph node metastasis (P < 0.001). These results indicate that p16 expression is associated with adverse prognostic factor of prostate cancer and suggest that p16 expression may provide useful information for treatment planning and identifying suitable candidates for upfront chemotherapy or androgen receptor axis-targeted therapy.
管理晚期激素初治前列腺癌（HNPC）是一个关键的公共卫生问题。因此，需要有用的预后标志物来选择那些将从最近引入的一线治疗中受益的患者。p16 表达是前列腺癌的一个不良预后标志物。本研究旨在确定 p16 表达是否可作为晚期 HNPC 的不良预后标志物。本研究共纳入 2010 年至 2013 年在爱知医科大学经活检诊断为 Gleason 评分≥8 的腺癌的 79 例患者。患者的中位年龄为 73 岁（范围 52-87 岁）。中位随访时间为 62 个月（范围 2-98 个月）。14 例患者的样本 p16 阳性。15 例患者死于前列腺癌，其中 10 例为 p16 阳性组。p16 阳性与临床 T 期（P<0.001）、IDC-P 的存在（P<0.001）、远处转移（P<0.001）和淋巴结转移（P<0.001）相关。这些结果表明，p16 表达与前列腺癌的不良预后因素有关，并提示 p16 表达可能为治疗计划提供有用信息，并确定适合一线化疗或雄激素受体轴靶向治疗的合适候选者。
